- Home » News and Events
NEWS & EVENTS
Our newest offerings and capabilities. Recent investments in network capacity, new and expanded services and expertise. Upcoming conferences and events.
Exelixis and Catalent Enter into Collaboration, License, and Exclusive Option Agreement to Develop Antibody-Drug Conjugates Leveraging SMARTag® Bioconjugation Technology
Sep 8, 2020
Exelixis, Inc. and Catalent today announced a partnership under which Catalent will develop multiple ADCs for Exelixis using Catalent’s proprietary SMARTag® technology.
Catalent Biologics Invests $50 Million to Add Third High-Speed Vial Line at its Bloomington, Indiana, Facility
Sep 2, 2020
Catalent today announced that it is investing $50 million to install an additional high-speed vial filling line at its Bloomington, Indiana, facility.
Technologies to Enhance Cell Line Productivity and Expand Antibody-Drug Conjugate Therapeutic Window to be Presented by Catalent Biologics at PEGS
Aug 25, 2020
Catalent today announced that two Catalent Biologics experts will present at the upcoming 16th Annual PEGS Boston Virtual Conference & Expo, taking place between Aug. 31 – September 4, 2020.
Catalent Signs Agreement with AstraZeneca to Expand Manufacturing Support for COVID-19 Vaccine AZD1222
Aug 24, 2020
Catalent Cell & Gene Therapy will provide drug substance manufacturing for the University of Oxford’s adenovirus vector-based vaccine at Catalent’s Harmans, Maryland gene therapy manufacturing facility.
Catalent to Discuss a Scalable Gene Therapy Manufacturing Process and Early Development Considerations for Orphan Drugs at Upcoming Industry Congress
Aug 18, 2020
Catalent today announced it will present at the upcoming World Orphan Drug Congress Annual Meeting, which will take place virtually on Aug. 24 – 26, 2020.
Catalent Gene Therapy Facility Receives FDA Approval as an Additional Manufacturing Site for AveXis’ Gene Therapy
Aug 6, 2020
Catalent will support the development, manufacturing, and clinical supply of Editas Medicine’s portfolio of in vivo CRISPR medicines and engineered cell medicines.
Catalent Enters into Strategic Partnership with Editas Medicine to Support Gene Editing Medicine Pipeline
Jul 29, 2020
Catalent will support the development, manufacturing, and clinical supply of Editas Medicine’s portfolio of in vivo CRISPR medicines and engineered cell medicines.
Catalent Biologics’ Executive to Discuss Manufacturing Scale-up During a Pandemic
Jul 22, 2020
Catalent today announced that Mike Riley, Region President, Biologics, North America, will present at the upcoming Disease Prevention & Control Summit, taking place virtually on July 28 – 29, 2020.
Catalent Biologics to Invest $30 Million to Create European Clinical Manufacturing Center of Excellence in Limoges, France
Jul 22, 2020
Catalent today announced that it plans to invest $30 million (€27 million) at its facility in Limoges, France, to create a European center of excellence for clinical biologics formulation development and drug product fill-finish services.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.